The Experts below are selected from a list of 159 Experts worldwide ranked by ideXlab platform
Jinquan Yu - One of the best experts on this subject based on the ideXlab platform.
-
pd 0 pr3 catalyzed intermolecular arylation of sp3 c h bonds
Journal of the American Chemical Society, 2009Co-Authors: Masayuki Wasa, Keary M Engle, Jinquan YuAbstract:Pd(0)-catalyzed intermolecular arylation of sp3 C−H bonds has been achieved using PR3/ArI. This protocol can be used to arylate a variety of aliphatic carboxylic acid derivatives, including a number of Bioactive Drug molecules. The use of fluorinated aryl iodides also allows for the introduction of fluorine into a molecule of interest.
-
Pd(0)/PR3-Catalyzed Intermolecular Arylation of sp3 C−H Bonds
Journal of the American Chemical Society, 2009Co-Authors: Masayuki Wasa, Keary M Engle, Jinquan YuAbstract:Pd(0)-catalyzed intermolecular arylation of sp3 C−H bonds has been achieved using PR3/ArI. This protocol can be used to arylate a variety of aliphatic carboxylic acid derivatives, including a number of Bioactive Drug molecules. The use of fluorinated aryl iodides also allows for the introduction of fluorine into a molecule of interest.
Amit K Goyal - One of the best experts on this subject based on the ideXlab platform.
-
advances in nanotechnology based carrier systems for targeted delivery of Bioactive Drug molecules with special emphasis on immunotherapy in Drug resistant tuberculosis a critical review
Drug Delivery, 2016Co-Authors: Jagdeep Singh, Tarun Garg, Goutam Rath, Amit K GoyalAbstract:AbstractFrom the early sixteenth and seventeenth centuries to the present day of life, tuberculosis (TB) still is a global health threat with some new emergence of resistance. This type of emergence poses a vital challenge to control TB cases across the world. Mortality and morbidity rates are high due to this new face of TB. The newer nanotechnology-based Drug-delivery approaches involving micro-metric and nano-metric carriers are much needed at this stage. These delivery systems would provide more advantages over conventional systems of treatment by producing enhanced therapeutic efficacy, uniform distribution of Drug molecule to the target site, sustained and controlled release of Drug molecules and lesser side effects. The main aim to develop these novel Drug-delivery systems is to improve the patient compliance and reduce therapy time. This article reviews and elaborates the new concepts and Drug-delivery approaches for the treatment of TB involving solid-lipid particulate Drug-delivery systems (soli...
-
Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
Current Pharmaceutical Design, 2015Co-Authors: Tarun Garg, Goutam Rath, R. S. R. Murthy, Umesh Gupta, Palakkod G. Vatsala, Amit K GoyalAbstract:Tuberculosis (TB) is an airborne communicable disease, mainly caused by aerobic, non-motile, rodshaped, weakly gram-positive, acid-fast tubercular bacillus Mycobacterium tuberculosis (MTb). Mycobacterium has worsened the problem in humans by acquiring various types of resistances like Multi-Drug resistance (MDR), Single-Drug resistance (SDR), and Extensive Drug resistance (XDR). Some clinical problems and challenges associated with conventional TB chemotherapy include poor patient compliance, longer duration of chemotherapy, lesser cell permeability, primary Drug resistance, difficulty in maintaining higher Drug concentrations at the infected site, and degradation of the Drug before reaching the target site. Thus, newer micrometric or nanometric carriers Drug delivery approaches are needed. Colloidal (vesicular and particulate) Drug carriers offer numerous advantages over conventional therapy such as better systemic bioavailability, rapid onset of therapeutic action, avoidance of first-pass metabolism, providing sustained and controlled release, fewer dosing frequencies, desired pharmacokinetic prole and route of administration. This review article present updates and fabrication of Drug delivery approaches for tuberculosis chemotherapy in order to improve patient compliance.
-
current nanotechnological strategies for effective delivery of Bioactive Drug molecules in the treatment of tuberculosis
Critical Reviews in Therapeutic Drug Carrier Systems, 2014Co-Authors: Mandeep Kaur, Tarun Garg, Goutam Rath, Amit K GoyalAbstract:Abstract Tuberculosis (TB) has gone from being a forgotten disease to a modern and recrudescent pathology from past decades. Some clinical problems and challenges associated with conventional TB chemotherapy include poor patient compliance, longer duration of chemotherapy, lesser cell permeability, primary Drug resistance, difficulty in maintaining higher Drug concentrations at the infected site, and degradation of the Drug before reaching the target site. Thus, newer Drug delivery approaches involving micrometric or nanometric carriers are needed. These delivery systems should provide advantages over conventional systems by producing optimum effectiveness to the target site, enhanced therapeutic efficacy, uniform distribution of the Drug throughout the target site, increased bioavailability and sustainability of the Drug, fewer side effects, and increased patient compliance. This article reviews recent updates and fabrication of Drug delivery approaches for tuberculosis chemotherapy involving vesicular Drug delivery systems (liposomes, niosomes, solid lipid nanoparticles), particulate Drug delivery systems (nanoparticles, microparticles, dendrimers), supramolecular Drug delivery systems (polymeric micelles), specialized Drug delivery systems (nanosuspensions, nanoemulsions, microemulsions, dry powders), complex conjugate Drug delivery systems (ISCOMs, cyclodextrin inclusion complexes), and other carrier-based Drug delivery systems in order to improve patient outcomes.
Masayuki Wasa - One of the best experts on this subject based on the ideXlab platform.
-
pd 0 pr3 catalyzed intermolecular arylation of sp3 c h bonds
Journal of the American Chemical Society, 2009Co-Authors: Masayuki Wasa, Keary M Engle, Jinquan YuAbstract:Pd(0)-catalyzed intermolecular arylation of sp3 C−H bonds has been achieved using PR3/ArI. This protocol can be used to arylate a variety of aliphatic carboxylic acid derivatives, including a number of Bioactive Drug molecules. The use of fluorinated aryl iodides also allows for the introduction of fluorine into a molecule of interest.
-
Pd(0)/PR3-Catalyzed Intermolecular Arylation of sp3 C−H Bonds
Journal of the American Chemical Society, 2009Co-Authors: Masayuki Wasa, Keary M Engle, Jinquan YuAbstract:Pd(0)-catalyzed intermolecular arylation of sp3 C−H bonds has been achieved using PR3/ArI. This protocol can be used to arylate a variety of aliphatic carboxylic acid derivatives, including a number of Bioactive Drug molecules. The use of fluorinated aryl iodides also allows for the introduction of fluorine into a molecule of interest.
Keary M Engle - One of the best experts on this subject based on the ideXlab platform.
-
pd 0 pr3 catalyzed intermolecular arylation of sp3 c h bonds
Journal of the American Chemical Society, 2009Co-Authors: Masayuki Wasa, Keary M Engle, Jinquan YuAbstract:Pd(0)-catalyzed intermolecular arylation of sp3 C−H bonds has been achieved using PR3/ArI. This protocol can be used to arylate a variety of aliphatic carboxylic acid derivatives, including a number of Bioactive Drug molecules. The use of fluorinated aryl iodides also allows for the introduction of fluorine into a molecule of interest.
-
Pd(0)/PR3-Catalyzed Intermolecular Arylation of sp3 C−H Bonds
Journal of the American Chemical Society, 2009Co-Authors: Masayuki Wasa, Keary M Engle, Jinquan YuAbstract:Pd(0)-catalyzed intermolecular arylation of sp3 C−H bonds has been achieved using PR3/ArI. This protocol can be used to arylate a variety of aliphatic carboxylic acid derivatives, including a number of Bioactive Drug molecules. The use of fluorinated aryl iodides also allows for the introduction of fluorine into a molecule of interest.
Jiang Chang - One of the best experts on this subject based on the ideXlab platform.
-
preparation in vitro bioactivity and Drug release property of well ordered mesoporous 58s Bioactive glass
Journal of Non-crystalline Solids, 2008Co-Authors: Jiang ChangAbstract:Bioactive glasses (BG) have proved to be able to chemically bond to living bone due to the formation of an apatite-like layer on its surface. In this paper, well-ordered mesoporous 58S Bioactive glass (M58S) was synthesized in aqueous solution by a two-step acid-catalyzed self-assembly process combined with hydrothermal treatment. The Drug release behavior of the M58S was investigated in phosphate buffered saline (PBS) at 37.5 °C for 20 days, and the assessment of in vitro bioactivity of M58S powders was carried out in simulated body fluid (SBF) at 37.5 °C. The results showed that M58S possessed good Drug release behavior due to its well-ordered mesoporous structure, and a higher ability to induce hydroxyapatite formation in SBF. Therefore, well-ordered mesoporous Bioactive glasses might be used as a Bioactive Drug release system for preparation of bone implant materials.
-
well ordered mesoporous Bioactive glasses mbg a promising Bioactive Drug delivery system
Journal of Controlled Release, 2006Co-Authors: Jiang ChangAbstract:The local Drug release system is considered to be an alternative to treat the bone infection. In this paper, well-ordered mesoporous Bioactive glasses (MBG) with high specific surface area have been synthesized in aqueous solution by a two-step acid-catalyzed self-assembly process combined with hydrothermal treatment. Gentamicin was encapsulated into the MBG by adsorption method and in vitro release of gentamicin from MBG was performed in distilled water and modified simulated body fluid (SBF), respectively. The results showed that the amount of Drug loading of MBG was three times more than that of conventional sol-gel 58S. The outcomes of Drug release in distilled water and in SBF showed that M58S effectively decreased the initial burst. During the release period, gentamicin was released from the M58S at a much lower release rate as compared to that from 58S after soaking in distilled water and SBF. Furthermore, the Drug release was sensitive to the pH and ionic concentration of the release medium suggesting possible controls of the release rate. In addition, in contrast to conventional sol-gel 58S, M58S had higher ability to induce hydroxyapatite (HAp) formation. Therefore, well-ordered mesoporous Bioactive glasses might be used as a Bioactive Drug release system for preparation of bone implant materials.
